West Pharmaceutical rockets on surging GLP-1 demand

West Pharmaceutical, a company that sells a tiny rubber component of GLP-1 pens, is up more than 20% after it reported earnings that crushed Wall Street estimates thanks to soaring demand for the weight-loss drugs.

The company reported adjusted earnings per share of $1.84, compared to the $1.51 analysts polled by FactSet were expecting. It also reported $766.5 million in sales, more than the $726.1 million the Street was penciling in.

Screenshot 2025-07-24 at 11.14.42 AM — Rubber elastomers used in GLP-1 pens (West Pharmaceutical Services)

The company attributed the strong report to growth in its GLP-1 elastomers, which are small rubber components that go into the pens that deliver the blockbuster weight-loss drugs made by Novo Nordisk and Eli Lilly. Those parts accounted for 8% of sales for the quarter, the company said.

More Markets

See all Markets

Matt Phillips1h

Palantir inks defense deal with Poland, touches new intraday high

Palantir Technologies touched a new intraday high of $192.83 early Monday, as the company rode the China trade truce rally in AI tech stocks and retail favorites.

Palantir also signed a new deal to supply the government of Poland with data, AI, and cybersecurity software, according to Bloomberg.

Polish Minister of Defense Wladyslaw Kosiniak-Kamysz and Palantir Chief Executive Officer Alex Karp signed the letter of intent on the deal, about which few details were released. Polish officials did signal that they were interested in Palantir software systems for “battlefield management” and logistics. Up more than 150% this year, Palantir reports Q3 earnings on November 3.

Poland Signs Palantir, Anduril Deals Amid Record Army Spending

J. Edward Moreno2h

Intellia tanks as it pauses late-stage CRISPR gene-editing trials after one patient was hospitalized

Intellia dropped sharply on Monday after it announced that it’s pausing two late-stage CRISPR gene-editing trials because one patient was hospitalized with liver damage.

Intellia had also disclosed in May that a patient had experienced elevated liver enzymes. The news is a major setback for the company, which currently has no products on the market and is working on a one-time treatment for heart and nerve conditions.

The news dragged down other companies working on CRISPR treatments, including Beam Therapeutics Inc, Crispr Therapeutics, Editas Medicine, and Prime Medicine.

Luke Kawa2h

Gold craters as retail traders pull money from commodity ETFs

As its fierce rally begins to fade, it looks like retail traders are waving au revoir to gold.

JPMorgan strategist Arun Jain noted that retail traders have pulled about $120 million from commodity ETFs as of 11 a.m. ET on Monday, a level that stands in the 0.4th percentile relative to its one-year average. The SPDR Gold Shares ETF is down 2.8% as of 11:53 a.m. ET after suffering its worst loss since April 2013 last Tuesday. That day, retail had pulled just $50 million from commodity ETFs by 11 a.m.

The five-session average daily flows into the product hit an all-time high of nearly $1.1 billion last Monday as gold and silver had effectively become the new meme stocks, displaying strong momentum and heavy options activity.

Luke Kawa3h

POET Technologies tumbles after announcing $150 million share offering to two new fundamental investment managers

POET Technologies is tumbling after announcing that it’s selling 20.7 million shares to raise approximately $150 million in an oversubscribed registered direct offering “by two new fundamental investors.”

Its prior $75 million raise through the sale of stock and warrants earlier this month is widely presumed to have been to MMCAP International, which was already its largest shareholder.

“We’ve been very pleased with the level of interest in POET by investors of all types — retail, institutional,” POET Executive Chairman and CEO Dr. Suresh Venkatesan recently told Sherwood News, saying that the company’s focus this year is to make sure that “the technology that we’re developing is truly manufacturable at scale and at wafer scale.”

The optical communications company has enjoyed elevated interest from retail investors recently as the AI boom raises the demand for data to be transferred as quickly and efficiently as possible. Last week, POET announced a $5 million order for its optical engines from a “leading systems integrator.”

Per the press release, POET “intends to use the net proceeds from this investment for corporate development, including targeted acquisitions, scaling up of R&D, acceleration of the light source business, expanding operations, and general working capital.”

Luke Kawa3h

JPMorgan recommends bullish options bets on Amazon and Meta ahead of earnings this week

JPMorgan analysts who cover Amazon and Meta are optimistic on the results these two hyperscalers will report this week, and Bram Kaplan, head of America equity derivatives strategy, has mapped out a similar approach to position for upside in both stocks.

Amazon is JPMorgan’s top pick among internet stocks for this earnings season, and both the Jassy-led and Zuckerberg-led companies are rated as “overweight” by the bank, in part because of tax benefits thanks to the OBBBA. The former reports on Thursday after the close, while the latter is slated to deliver results on Wednesday postmarket.

Kaplan’s tactic is to position for strength — but not too much strength — from both stocks as investors react to the quarterly figures. His recommendations:

Buy the Amazon $235 strike call that expires this Friday while selling the $245 strike;
But the Meta $780 strike call that expires this Friday while selling the $805 strike.

Both are call spread trades, but there’s a bit of a different rationale for why in each company.

Skew on Amazon is fairly flat, per Kaplan. That is, there’s not too big of a difference between the implied volatility of close-to-the-money call options and those that are further out of the money, making call spreads relatively cost-efficient. In the case of Meta, Kaplan says that earnings volatility is “cheap,” with the options market implying a move of plus or minus 6.1% coming into this week, versus an average one-day reaction of plus or minus 7.5% going back to Q3 2014. However, it’s a very well owned stock, he noted, which could cause a more muted reaction even in the event of strong results.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.